{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:05:35Z","timestamp":1761843935960},"publisher-location":"Berlin, Heidelberg","reference-count":154,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642012211"},{"type":"electronic","value":"9783642012228"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-3-642-01222-8_12","type":"book-chapter","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T09:21:41Z","timestamp":1257499301000},"page":"173-187","source":"Crossref","is-referenced-by-count":29,"title":["Bortezomib"],"prefix":"10.1007","author":[{"given":"Hermann","family":"Einsele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"key":"12_CR1_12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","volume":"8","author":"J Adams","year":"1998","unstructured":"Adams J, Behnke M, Chen S et al (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8: 333\u2013338","journal-title":"Bioorg Med Chem Lett"},{"key":"12_CR2_12","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615\u20132622","journal-title":"Cancer Res"},{"key":"12_CR3_12","first-page":"2505","volume":"8","author":"C Aghajanian","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505\u20132511","journal-title":"Clin Cancer Res"},{"key":"12_CR4_12","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1200\/JCO.2005.16.006","volume":"23","author":"C Aghajanian","year":"2005","unstructured":"Aghajanian C, Dizon DS, Sabbatini P et al (2005) Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23:5943\u20135949","journal-title":"J Clin Oncol"},{"issue":"4","key":"12_CR4a_12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","volume":"80","author":"R Alexanian","year":"1992","unstructured":"Alexanian R, Dimopoulos MA, Delasalle K, et al (1992) Primary dexamethasone treatment of multiple myeloma. Blood 80(4):887\u2013890","journal-title":"Blood"},{"key":"12_CR5_12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ajh.2830330203","volume":"33","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86\u201389","journal-title":"Am J Hematol"},{"key":"12_CR6_12","doi-asserted-by":"crossref","first-page":"128a","DOI":"10.1182\/blood.V110.11.411.411","volume":"110","author":"M Alsina","year":"2007","unstructured":"Alsina M, Trudel S, Vallone M et al (2007) Phase I single agent antitumor activity of twice weekly-consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malig\u00adnancies [abstract 411]. Blood 110:128a","journal-title":"Blood"},{"key":"12_CR7_12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe francais du myelome. New Engl J Med 335:91\u201397","journal-title":"New Engl J Med"},{"key":"12_CR8_12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","volume":"103","author":"B Barlogie","year":"2004","unstructured":"Barlogie B, Shaughnessy JD, Tricot G et al (2004) Treatment of multiple myeloma. Blood 103: 20\u201332","journal-title":"Blood"},{"key":"12_CR9_12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdl316","volume":"18","author":"A Belch","year":"2007","unstructured":"Belch A, Kouroukis CT, Crump M et al (2007) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18:116\u2013121","journal-title":"Ann Oncol"},{"key":"12_CR10_12","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1158\/1078-0432.CCR-07-2219","volume":"14","author":"J Bennouna","year":"2008","unstructured":"Bennouna J, Delord JP, Campone M, Pinel M-C (2008) Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 14:1610\u20131617","journal-title":"Clin Cancer Res"},{"key":"12_CR11_12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","volume":"24","author":"JR Berenson","year":"2006","unstructured":"Berenson JR, Yang HH, Sadler K et al (2006) Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937\u2013944","journal-title":"J Clin Oncol"},{"key":"12_CR12_12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00277-006-0220-3","volume":"86","author":"SE Biehn","year":"2007","unstructured":"Biehn SE, Moore DT, Voorhees PM et al (2007) Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86:211\u2013216","journal-title":"Ann Hematol"},{"key":"12_CR13_12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.thj.6200115","volume":"2","author":"J Blad\u00e9","year":"2001","unstructured":"Blad\u00e9 J, San Miguel JF, Fontanillas M et al (2001) Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2:272\u2013278","journal-title":"Hematol J"},{"key":"12_CR14_12","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1200\/JCO.2004.12.185","volume":"22","author":"SM Blaney","year":"2004","unstructured":"Blaney SM, Bernstein M, Neville K et al (2004) Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children\u2019s Oncology Group study (ADVL0015). J Clin Oncol 22:4804\u20134809","journal-title":"J Clin Oncol"},{"key":"12_CR15_12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1242\/dev.02276","volume":"133","author":"B Bowerman","year":"2006","unstructured":"Bowerman B, Kurz T (2006) Degrade to create: developmental requirements for ubiquitin-mediated proteolysis during early C. elegans embryogenesis. Development 133:773\u2013784","journal-title":"Development"},{"key":"12_CR16_12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/12043","volume":"1","author":"BC Braun","year":"1999","unstructured":"Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D, Schmidt M (1999) The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol 1:221\u2013226","journal-title":"Nat Cell Biol"},{"issue":"Pt 1","key":"12_CR17_12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1042\/0264-6021:3460155","volume":"346","author":"P Brooks","year":"2000","unstructured":"Brooks P, Fuertes G, Murray RZ, Bose S, Knecht E, Rechsteiner MC, Hendil KB, Tanaka K, Dyson J, Rivett J (2000) Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 346(Pt 1):155\u2013161","journal-title":"Biochem J"},{"key":"12_CR18_12","first-page":"934","volume":"87","author":"M Cavo","year":"2002","unstructured":"Cavo M, Benni M, Ronconi S et al (2002) Melphalan-prednisone versus alternating combination VAD\/MP or VND\/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica 87: 934\u2013942","journal-title":"Haematologica"},{"key":"12_CR19_12","doi-asserted-by":"crossref","first-page":"1010a","DOI":"10.1182\/blood.V108.11.1010.1010","volume":"108","author":"AA Chanan-Khan","year":"2006","unstructured":"Chanan-Khan AA, Padmanabhan S, Miller KC et al (2006) Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rate in patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma. Updated data presented at the 2006 Annual Meeting of the American Society of Hematology. Blood 108:1010a","journal-title":"Blood"},{"key":"12_CR20_12","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","volume":"109","author":"AA Chanan-Khan","year":"2007","unstructured":"Chanan-Khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604\u20132606","journal-title":"Blood"},{"key":"12_CR21_12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","volume":"87","author":"D Chauhan","year":"1996","unstructured":"Chauhan D, Uchiyama H, Akbarali Y et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-\u03baB. Blood 87: 1104\u20131112","journal-title":"Blood"},{"key":"12_CR22_12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","volume":"8","author":"D Chauhan","year":"2005","unstructured":"Chauhan D, Catley L, Li G et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8: 407\u2013419","journal-title":"Cancer Cell"},{"key":"12_CR23_12","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","volume":"25","author":"CI Chen","year":"2007","unstructured":"Chen CI, Kouroukis CT, White D et al (2007) Bortezomib is active in patients with untreated or relapsed Waldenstrom\u2019s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1570\u20131575","journal-title":"J Clin Oncol"},{"key":"12_CR24_12","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1158\/1078-0432.CCR-07-2176","volume":"14","author":"H Choy","year":"2008","unstructured":"Choy H, Park C, Yao M (2008) Current status and future prospect for satraplatin: an oral platinum analogue. Clin Cancer Res 14:1618\u20131623","journal-title":"Clin Cancer Res"},{"key":"12_CR25_12","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/sj.cdd.4401692","volume":"12","author":"A Ciechanover","year":"2005","unstructured":"Ciechanover A (2005) Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 12:1178\u20131190","journal-title":"Cell Death Differ"},{"key":"12_CR26_12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q","volume":"22","author":"A Ciechanover","year":"2000","unstructured":"Ciechanover A, Orian A, Schwartz AL (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22:442\u2013451","journal-title":"Bioessays"},{"key":"12_CR27_12","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","volume":"10","author":"J Cortes","year":"2004","unstructured":"Cortes J, Thomas D, Koller C et al (2004) Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10: 3371\u20133376","journal-title":"Clin Cancer Res"},{"key":"12_CR28_12","first-page":"3535","volume":"61","author":"JC Cusack Jr","year":"2001","unstructured":"Cusack JC Jr, Liu R, Houston M et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-\u03baB inhibition. Cancer Res 61:3535\u20133540","journal-title":"Cancer Res"},{"key":"12_CR29_12","doi-asserted-by":"crossref","first-page":"1009a","DOI":"10.1182\/blood.V108.11.1009.1009","volume":"108","author":"FE Davies","year":"2006","unstructured":"Davies FE, Wu P, Srikanth M et al (2006) The combination of cyclophosphamide, Velcade and dexamethasone (CVD) induces high response rates with minimal toxicity compared to Velcade alone (V) and Velcade plus dexamethasone (VD). Updated data presented at the 2006 Annual Meeting of the American Society of Hematology. Blood 108:1009a","journal-title":"Blood"},{"key":"12_CR30_12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/bjc.1998.183","volume":"77","author":"J Delic","year":"1998","unstructured":"Delic J, Masdehors P, Omura S et al (1998) The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-\u03b1-initiated apoptosis. Br J Cancer 77: 1103\u20131107","journal-title":"Br J Cancer"},{"key":"12_CR31_12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cell.2007.05.007","volume":"129","author":"GN Demartino","year":"2007","unstructured":"Demartino GN, Gillette TG (2007) Proteasomes: machines for all reasons. Cell 129:659\u2013662","journal-title":"Cell"},{"key":"12_CR32_12","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA et al (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383\u20136391","journal-title":"Cancer Res"},{"key":"12_CR33_12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","volume":"14","author":"MA Dimopoulos","year":"2003","unstructured":"Dimopoulos MA, Pouli A, Zervas K et al (2003) Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 14: 1039\u20131044","journal-title":"Ann Oncol"},{"key":"12_CR34_12","first-page":"1655","volume":"90","author":"MA Dimopoulos","year":"2005","unstructured":"Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al (2005) Treatment of relapsed or refractory Waldenstrom\u2019s macroglobulinemia with bortezomib. Haematologica 90:1655\u20131658","journal-title":"Haematologica"},{"key":"12_CR35_12","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1158\/1078-0432.CCR-04-2068","volume":"11","author":"GK Dy","year":"2005","unstructured":"Dy GK, Thomas JP, Wilding G et al (2005) A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 11:3410\u20133416","journal-title":"Clin Cancer Res"},{"key":"12_CR36_12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00109-003-0422-2","volume":"81","author":"PJ Elliott","year":"2003","unstructured":"Elliott PJ, Zollner TM, Boehncke WH (2003) Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81:235\u2013245","journal-title":"J Mol Med"},{"key":"12_CR37_12","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","volume":"107","author":"T Facon","year":"2006","unstructured":"Facon T, Mary JY, Pegourie B et al (2006) Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107:1292\u20131298","journal-title":"Blood"},{"key":"12_CR38_12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/anie.200390115","volume":"42","author":"RH Feling","year":"2003","unstructured":"Feling RH, Buchanan GO, Mincer TJ et al (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42:355\u2013357","journal-title":"Angew Chem Int Ed Engl"},{"key":"12_CR39_12","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1074\/jbc.273.15.8545","volume":"273","author":"G Fenteany","year":"1998","unstructured":"Fenteany G, Schreiber SL (1998) Lactacystin, proteasome function, and cell fate. J Biol Chem 273:8545\u20138548","journal-title":"J Biol Chem"},{"key":"12_CR40_12","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867\u20134874","journal-title":"J Clin Oncol"},{"key":"12_CR41_12","first-page":"273","volume":"91","author":"J Friedman","year":"2006","unstructured":"Friedman J, Al-Zoubi A, Kaminski M et al (2006) A new model predicting at least a very good partial response in patients with multiple myeloma after 2 cycles of Velcade-based therapy. Updated data presented at the 2006 Annual Meeting of the European Hematology Association. Haema\u00adtologica 91:273","journal-title":"Haematologica"},{"key":"12_CR42_12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4161\/cbt.1.4.2","volume":"1","author":"SY Fuchs","year":"2002","unstructured":"Fuchs SY (2002) The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol Ther 1:337\u2013341","journal-title":"Cancer Biol Ther"},{"key":"12_CR43_12","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-07-2179","volume":"14","author":"O Gautschi","year":"2008","unstructured":"Gautschi O, Heighway J, Mack PC et al (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1624\u20131633","journal-title":"Clin Cancer Res"},{"key":"12_CR44_12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1586\/14737140.6.3.343","volume":"6","author":"MA Gertz","year":"2006","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A et al (2006) High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expet Rev Anticancer Ther 6: 343\u2013360","journal-title":"Expet Rev Anticancer Ther"},{"key":"12_CR45_12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nature02263","volume":"426","author":"AL Goldberg","year":"2003","unstructured":"Goldberg AL (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426:895\u2013899","journal-title":"Nature"},{"key":"12_CR46_12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P et al (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:667\u2013675","journal-title":"J Clin Oncol"},{"key":"12_CR47_12","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/80992","volume":"7","author":"M Groll","year":"2000","unstructured":"Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D (2000) Agated channel into the proteasome core particle. Nat Struct Biol 7:1062\u20131067","journal-title":"Nat Struct Biol"},{"key":"12_CR48_12","doi-asserted-by":"crossref","first-page":"139a","DOI":"10.1182\/blood.V110.11.139.139","volume":"110","author":"JL Harousseau","year":"2007","unstructured":"Harousseau JL, Mathiot C, Attal M et al (2007) VELCADE\/dexamethasone (Vel\/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005\/01 trial. Blood 110:139a","journal-title":"Blood"},{"key":"12_CR49_12","doi-asserted-by":"publisher","first-page":"455s","DOI":"10.1200\/JCO.2007.13.2415","volume":"26","author":"JL Harousseau","year":"2008","unstructured":"Harousseau JL, Mathiot C, Attal M et al (2008) Bortezomib\/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005\/01 trial. J Clin Oncol 26:455s","journal-title":"J Clin Oncol"},{"key":"12_CR50_12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2141.2004.05186.x","volume":"127","author":"JM Hernandez","year":"2004","unstructured":"Hernandez JM, Garcia-Sanz R, Golvano E et al (2004) Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 127:159\u2013164","journal-title":"Br J Haematol"},{"key":"12_CR51_12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425\u2013479","journal-title":"Annu Rev Biochem"},{"key":"12_CR51a_12","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Podar K. et al (2001). Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol.(6):607\u2013612. Review","DOI":"10.1016\/S0093-7754(01)90033-8"},{"key":"12_CR52_12","doi-asserted-by":"publisher","first-page":"16639","DOI":"10.1074\/jbc.M200360200","volume":"277","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Chauhan D, Richardson P et al (2002) NF-\u03baB as a therapeutic target in multiple myeloma. J Biol Chem 277:16639\u201316647","journal-title":"J Biol Chem"},{"key":"12_CR53_12","doi-asserted-by":"publisher","first-page":"8766","DOI":"10.1038\/sj.onc.1208118","volume":"23","author":"T Hideshima","year":"2004","unstructured":"Hideshima T, Podar K, Chauhan D et al (2004) p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23:8766\u20138776","journal-title":"Oncogene"},{"key":"12_CR54_12","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1073\/pnas.0503221102","volume":"102","author":"T Hideshima","year":"2005","unstructured":"Hideshima T, Bradner JE, Wong J et al (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 102:8567\u20138572","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12_CR55_12","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","volume":"107","author":"T Hideshima","year":"2006","unstructured":"Hideshima T, Catley L, Yasui H et al (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053\u20134062","journal-title":"Blood"},{"key":"12_CR56_12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.chembiol.2007.03.008","volume":"14","author":"YK Ho","year":"2007","unstructured":"Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, Kim KB (2007) LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol 14:419\u2013430","journal-title":"Chem Biol"},{"key":"12_CR57_12","doi-asserted-by":"publisher","first-page":"659a","DOI":"10.1182\/blood-2003-05-1442","volume":"104","author":"K Hollmig","year":"2004","unstructured":"Hollmig K, Stover J, Talamo G et al (2004) Bortezomib (Velcade\u2122) + Adriamycin\u2122 + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). Updated data presented at the 2004 Annual Meeting of the American Society of Hematology. Blood 104: 659a","journal-title":"Blood"},{"key":"12_CR58_12","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1006\/bbrc.1995.2878","volume":"217","author":"KT Imajoh-Ohmi","year":"1995","unstructured":"Imajoh-Ohmi KT, Sugiyama S, Tanaka K, Omura S, Kikuchi H (1995) Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217:1070\u20131077","journal-title":"Biochem Biophys Res Commun"},{"key":"12_CR59_12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165\u2013172","journal-title":"Br J Haematol"},{"key":"12_CR60_12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.20888","volume":"103","author":"S Jagannath","year":"2005","unstructured":"Jagannath S, Barlogie B, Berenson JR et al (2005) Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103:1195\u20131200","journal-title":"Cancer"},{"key":"12_CR61_12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.leu.2404442","volume":"21","author":"S Jagannath","year":"2007","unstructured":"Jagannath S, Richardson PG, Sonneveld P et al (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21:151\u2013157","journal-title":"Leukemia"},{"key":"12_CR62_12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrm731","volume":"3","author":"V Jesenberger","year":"2002","unstructured":"Jesenberger V, Jentsch S (2002) Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3:112\u20131121","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12_CR63_12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.coi.2003.11.004","volume":"16","author":"PM Kloetzel","year":"2004","unstructured":"Kloetzel PM, Ossendorp F (2004) Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 16: 76\u201381","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"12_CR63a_12","first-page":"346","volume":"49","author":"S Knop","year":"2008","unstructured":"Knop S, Einsele H, Bargou R, et al (2008) Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment. Leuk Lymphoma. 2008 Feb;49(2):346\u2013349","journal-title":"Leuk Lymphoma. 2008 Feb"},{"key":"12_CR64_12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0092-8674(00)80574-7","volume":"96","author":"M Koegl","year":"1999","unstructured":"Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S (1999) A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635\u2013644","journal-title":"Cell"},{"key":"12_CR65_12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1097-2765(01)00274-X","volume":"7","author":"A Kohler","year":"2001","unstructured":"Kohler A, Cascio P, Leggett DS, Woo KM, Goldberg AL, Finley D (2001) The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol Cell 7:1143\u20131152","journal-title":"Mol Cell"},{"key":"12_CR66_12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.leukres.2004.11.004","volume":"29","author":"MH Kropff","year":"2005","unstructured":"Kropff MH, Bisping G, Wenning D et al (2005a) Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 29: 587\u2013590","journal-title":"Leuk Res"},{"key":"12_CR67_12","doi-asserted-by":"crossref","first-page":"716a","DOI":"10.1182\/blood.V106.11.2549.2549","volume":"106","author":"M Kropff","year":"2005","unstructured":"Kropff M, Bisping G, Liebisch P et al (2005b) Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Updated data presented at the 2005 Annual Meeting of the American Society of Hematology. Blood 106:716a","journal-title":"Blood"},{"key":"12_CR68_12","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM et al (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood 110:3281\u20133290","journal-title":"Blood"},{"key":"12_CR69_12","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV (2004) Multiple myeloma. New Eng J Med 351:1860\u20131873","journal-title":"New Eng J Med"},{"key":"12_CR70_12","doi-asserted-by":"crossref","first-page":"568s","DOI":"10.1200\/jco.2005.23.16_suppl.568","volume":"23","author":"SJ Lee","year":"2005","unstructured":"Lee SJ, Richardson PG, Sonneveld P et al (2005) Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): results from APEX study. J Clin Oncol 23:568s","journal-title":"J Clin Oncol"},{"key":"12_CR71_12","first-page":"1643","volume":"14","author":"JL Lee","year":"2008","unstructured":"Lee JL, Swain SM (2008) The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 14:1643\u20131649","journal-title":"Clin Cancer Res"},{"key":"12_CR72_12","first-page":"281","volume":"91","author":"F Leoni","year":"2006","unstructured":"Leoni F, Casini C, Breschi C et al (2006) Low dose bortezomib, dexamethasone, thalidomide plus liposomal doxorubicin in relapsed and refractory myeloma. Updated data presented at the 2006 Annual Meeting of the European Hematology Association. Haematologica 91:281","journal-title":"Haematologica"},{"key":"12_CR73_12","first-page":"841","volume":"1","author":"YH Ling","year":"2002","unstructured":"Ling YH, Liebes L, Ng B et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841\u2013849","journal-title":"Mol Cancer Ther"},{"key":"12_CR74_12","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","volume":"106","author":"S Lonial","year":"2005","unstructured":"Lonial S, Waller EK, Richardson PG et al (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106: 3777\u20133784","journal-title":"Blood"},{"key":"12_CR75_12","doi-asserted-by":"publisher","first-page":"14671","DOI":"10.1074\/jbc.273.24.14671","volume":"273","author":"TW Loo","year":"1998","unstructured":"Loo TW, Clarke DM (1998) Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem 273:14671\u201314674","journal-title":"J Biol Chem"},{"key":"12_CR76_12","first-page":"1724","volume":"7","author":"TW Loo","year":"1999","unstructured":"Loo TW, Clarke DM (1999) The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 7:1724\u20131732","journal-title":"FASEB J"},{"key":"12_CR77_12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00280-006-0259-9","volume":"59","author":"C Ma","year":"2007","unstructured":"Ma C, Mandrekar SJ, Alberts SR et al (2007) A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59: 207\u2013215","journal-title":"Cancer Chemother Pharmacol"},{"key":"12_CR77a_12","unstructured":"Ma MH, Yang HH, Parker K et al (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. (3): 1136\u20131144"},{"key":"12_CR78_12","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","volume":"108","author":"MV Mateos","year":"2006","unstructured":"Mateos MV, Hernandez JM, Hernandez MT et al (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study. Blood 108:2165\u20132172","journal-title":"Blood"},{"key":"12_CR79_12","first-page":"180","volume":"92","author":"MV Mateos","year":"2007","unstructured":"Mateos MV, Hernandez JM, Hernandez MT et al (2007) Frontline VMP in elderly MM patients: extended follow-up. Haematologica 92:180","journal-title":"Haematologica"},{"key":"12_CR80_12","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/1078-0432.CCR-05-1942","volume":"12","author":"WA Messersmith","year":"2006","unstructured":"Messersmith WA, Baker SD, Lassiter L et al (2006) Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12:1270\u20131275","journal-title":"Clin Cancer Res"},{"key":"12_CR81_12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","volume":"107","author":"CS Mitsiades","year":"2006","unstructured":"Mitsiades CS, Mitsiades NS, McMullan CJ et al (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood 107:1092\u20131100","journal-title":"Blood"},{"key":"12_CR82_12","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1182\/blood.V99.11.4079","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Biologic sequelae of nuclear factor-\u03baB blockade in multiple myeloma: therapeutic applications. Blood 99:4079\u20134086","journal-title":"Blood"},{"key":"12_CR83_12","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 \u00adpotentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377\u20132380","journal-title":"Blood"},{"key":"12_CR84_12","doi-asserted-by":"crossref","first-page":"612s","DOI":"10.1200\/jco.2005.23.16_suppl.6714","volume":"23","author":"A Mohrbacher","year":"2005","unstructured":"Mohrbacher A, Levine AM (2005) Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients. J Clin Oncol 23:612s","journal-title":"J Clin Oncol"},{"key":"12_CR85_12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrm1049","volume":"4","author":"M Muratani","year":"2003","unstructured":"Muratani M, Tansey WP (2003) How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4:192\u2013201","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12_CR86_12","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Myeloma Trialists\u2019 Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 633 patients from 27 randomized trials. J Clin Oncol 16:3832\u20133842","journal-title":"J Clin Oncol"},{"key":"12_CR87_12","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/01.LAB.0000022226.23741.37","volume":"82","author":"C Naujokat","year":"2002","unstructured":"Naujokat C, Hoffmann S (2002) Role and function of the 26 S proteasome in proliferation and apoptosis. Lab Invest 82:965\u2013980","journal-title":"Lab Invest"},{"key":"12_CR88_12","doi-asserted-by":"publisher","first-page":"11510","DOI":"10.1158\/0008-5472.CAN-05-2394","volume":"65","author":"ST Nawrocki","year":"2005","unstructured":"Nawrocki ST, Carew JS, Dunner K Jr et al (2005a) Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 65:11510\u201311519","journal-title":"Cancer Res"},{"key":"12_CR89_12","doi-asserted-by":"publisher","first-page":"11658","DOI":"10.1158\/0008-5472.CAN-05-2370","volume":"65","author":"ST Nawrocki","year":"2005","unstructured":"Nawrocki ST, Carew JS, Pino MS et al (2005b) Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65:11658\u201311666","journal-title":"Cancer Res"},{"key":"12_CR90_12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.leu.2404444","volume":"21","author":"A Nencioni","year":"2007","unstructured":"Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia 21: 30\u201336","journal-title":"Leukemia"},{"key":"12_CR91_12","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM et al (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107:4907\u20134916","journal-title":"Blood"},{"key":"12_CR92_12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C et al (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non\u2013Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol 23:676\u2013684","journal-title":"J Clin Oncol"},{"key":"12_CR93_12","first-page":"4342","volume":"58","author":"RZ Orlowski","year":"1998","unstructured":"Orlowski RZ, Eswara JR, Lafond-Walker A et al (1998) Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res 58: 4342\u20134348","journal-title":"Cancer Res"},{"key":"12_CR94_12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1471-4914(02)02375-4","volume":"8","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Baldwin AS (2002) NF-\u03baB as a therapeutic target in cancer. Trends Mol Med 8:385\u2013389","journal-title":"Trends Mol Med"},{"key":"12_CR95_12","doi-asserted-by":"publisher","first-page":"27864","DOI":"10.1074\/jbc.M201519200","volume":"277","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Small GW, Shi YY (2002a) Evidence that inhibition of p44\/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277:27864\u201327871","journal-title":"J Biol Chem"},{"key":"12_CR96_12","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002b) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420\u20134427","journal-title":"J Clin Oncol"},{"key":"12_CR97_12","doi-asserted-by":"crossref","first-page":"76a","DOI":"10.1182\/blood.V106.11.248.248","volume":"106","author":"RZ Orlowski","year":"2005","unstructured":"Orlowski RZ, Kuhn DJ, Small GW, Michaud C, Orlowski M (2005a) Identification of novel inhibitors that specifically target the immunoproteasome, and selectively induce apoptosis in multiple myeloma and other immunoproteasome-expressing model systems [abstract 248]. Blood 106:76a","journal-title":"Blood"},{"key":"12_CR98_12","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","volume":"105","author":"RZ Orlowski","year":"2005","unstructured":"Orlowski RZ, Voorhees PM, Garcia RA et al (2005b) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058\u20133065","journal-title":"Blood"},{"key":"12_CR99_12","doi-asserted-by":"crossref","first-page":"124a","DOI":"10.1182\/blood.V108.11.124.124","volume":"108","author":"RZ Orlowski","year":"2006","unstructured":"Orlowski RZ, Zhuang SH, Parekh T et al (2006) DOXIL-MMY-3001 Study Investigators. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed\/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study. Updated data presented at the 2006 Annual Meeting of the American Society of Hematology. Blood 108: 124a","journal-title":"Blood"},{"key":"12_CR100_12","doi-asserted-by":"crossref","first-page":"127a","DOI":"10.1182\/blood.V110.11.127.127","volume":"110","author":"RZ Orlowski","year":"2007","unstructured":"Orlowski RZ, Stewart K, Vallone M et al (2007) Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase I results [abstract 409]. Blood 110:127a","journal-title":"Blood"},{"key":"12_CR101_12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825\u2013831","journal-title":"Lancet"},{"key":"12_CR102_12","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","volume":"109","author":"A Palumbo","year":"2007","unstructured":"Palumbo A, Ambrosini MT, Benevolo G et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767\u20132772","journal-title":"Blood"},{"key":"12_CR103_12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3324\/haematol.11535","volume":"93","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Schlag R, Khuageva N et al (2008) Prolonged therapy with bortezomib plus melphalan\u2013prednisone (VMP) results in improved quality and duration of response in the phase III VISTA study in previously untreated multiple myeloma (MM). Haematologica 93:83","journal-title":"Haematologica"},{"key":"12_CR104_12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","volume":"22","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D et al (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108\u20132121","journal-title":"J Clin Oncol"},{"key":"12_CR105_12","doi-asserted-by":"crossref","first-page":"697a","DOI":"10.1182\/blood.V106.11.697.697","volume":"106","author":"R Popat","year":"2005","unstructured":"Popat R, Goff L, Oakervee HE et al (2005) Changes in Mcl-1 and Bim expression with bortezomib and melphalan therapy for multiple myeloma. Blood 106:697a","journal-title":"Blood"},{"key":"12_CR106_12","doi-asserted-by":"crossref","first-page":"1011a","DOI":"10.1182\/blood.V108.11.3542.3542","volume":"108","author":"R Popat","year":"2006","unstructured":"Popat R, Williams C, Cook M et al (2006) A phase I\/II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma. Updated data presented at the 2006 Annual Meeting of the American Society of Hematology. Blood 108:1011a","journal-title":"Blood"},{"key":"12_CR107_12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630\u2013639","journal-title":"J Clin Oncol"},{"key":"12_CR108_12","doi-asserted-by":"crossref","first-page":"1009a","DOI":"10.1182\/blood.V108.11.1009.1009","volume":"108","author":"DE Reece","year":"2006","unstructured":"Reece DE, Piza G, Trudel S et al (2006) A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed\/refractory multiple myeloma. Updated data presented at the 2006 Annual Meeting of the American Society of Hematology. Blood 108:1009a","journal-title":"Blood"},{"key":"12_CR109_12","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med 348: 2609\u20132617","journal-title":"New Engl J Med"},{"key":"12_CR110_12","doi-asserted-by":"crossref","first-page":"715a","DOI":"10.1182\/blood.V106.11.715.715","volume":"106","author":"P Richardson","year":"2005","unstructured":"Richardson P, Sonneveld P, Schuster M et al (2005a) Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Updated data presented at the 2005 Annual Meeting of the American Society of Hematology. Blood 106:715a","journal-title":"Blood"},{"key":"12_CR111_12","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005b) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 352:2487\u20132498","journal-title":"New Engl J Med"},{"key":"12_CR112_12","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/cncr.21740","volume":"106","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Barlogie B, Berenson J et al (2006a) Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 106: 1316\u20131319","journal-title":"Cancer"},{"key":"12_CR113_12","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S et al (2006b) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113\u20133120","journal-title":"J Clin Oncol"},{"key":"12_CR114_12","doi-asserted-by":"crossref","first-page":"124a","DOI":"10.1182\/blood.V108.11.124.124","volume":"108","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Jagannath S, Avigan DE et al (2006c) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and\/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Updated data presented at the 2006 Annual Meeting of the American Society of Hematology. Blood 108:124a","journal-title":"Blood"},{"key":"12_CR115_12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/01.cco.0000245320.34658.bd","volume":"18","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Mitsiades C, Ghobrial I et al (2006d) Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol 18:598\u2013608","journal-title":"Curr Opin Oncol"},{"key":"12_CR116_12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","volume":"57","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006e) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33\u201347","journal-title":"Annu Rev Med"},{"key":"12_CR117_12","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster M et al (2007a) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110: 3557\u20133560","journal-title":"Blood"},{"key":"12_CR118_12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","volume":"137","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2007b) Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 137:429\u2013435","journal-title":"Br J Haematol"},{"key":"12_CR119_12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/cncr.21662","volume":"106","author":"RM Rifkin","year":"2006","unstructured":"Rifkin RM, Gregory SA, Mohrbacher A et al (2006) Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 106:848\u2013858","journal-title":"Cancer"},{"key":"12_CR120_12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/1389203043379774","volume":"5","author":"AJ Rivett","year":"2004","unstructured":"Rivett AJ, Hearn AR (2004) Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr Protein Pept Sci 5:153\u2013161","journal-title":"Curr Protein Pept Sci"},{"key":"12_CR121_12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/0264-6021:3440477","volume":"344","author":"JD Robertson","year":"1999","unstructured":"Robertson JD, Datta K, Biswal SS, Kehrer JP (1999) Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem J 344:477\u2013485","journal-title":"Biochem J"},{"key":"12_CR122_12","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-06-0066","volume":"5","author":"S Ruiz","year":"2006","unstructured":"Ruiz S, Krupnik Y, Keating M et al (2006) The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 5:1836\u20131843","journal-title":"Mol Cancer Ther"},{"key":"12_CR123_12","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/cncr.22280","volume":"107","author":"DP Ryan","year":"2006","unstructured":"Ryan DP, O\u2019Neil BH, Supko JG et al (2006) A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107: 2688\u20132697","journal-title":"Cancer"},{"key":"12_CR124_12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/sj.leu.2404459","volume":"21","author":"V Sagaster","year":"2007","unstructured":"Sagaster V, Ludwig H, Kaufmann H et al (2007) Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 21:164\u2013168","journal-title":"Leukemia"},{"key":"12_CR125_12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Eng J Med 359:906\u2013917","journal-title":"New Eng J Med"},{"key":"12_CR126_12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1515\/BC.2005.085","volume":"386","author":"M Schmidt","year":"2005","unstructured":"Schmidt M, Hanna J, Elsasser S, Finley D (2005) Proteasome-associated proteins: regulation of a proteolytic machine. Biol Chem 386:725\u2013737","journal-title":"Biol Chem"},{"key":"12_CR127_12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10549-006-9232-x","volume":"100","author":"YY Shi","year":"2006","unstructured":"Shi YY, Small GW, Orlowski RZ (2006) Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 100:33\u201347","journal-title":"Breast Cancer Res Treat"},{"key":"12_CR128_12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1042\/bj3170385","volume":"317","author":"K Shinohara","year":"1996","unstructured":"Shinohara K, Tomioka M, Nakano H et al (1996) Apoptosis induction resulting from proteasome inhibition. Biochem J 317:385\u2013388","journal-title":"Biochem J"},{"key":"12_CR129_12","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/S0960-894X(99)00376-5","volume":"9","author":"N Sin","year":"1999","unstructured":"Sin N, Kim KB, Elofsson M et al (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9:2283\u20132288","journal-title":"Bioorg Med Chem Lett"},{"key":"12_CR130_12","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1124\/mol.104.003400","volume":"66","author":"GW Small","year":"2004","unstructured":"Small GW, Shi YY, Edmund NA et al (2004) Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66:1478\u20131490","journal-title":"Mol Pharmacol"},{"key":"12_CR131_12","first-page":"146","volume":"90","author":"P Sonneveld","year":"2005","unstructured":"Sonneveld P, Richardson PG, Schuster MW et al (2005) Bortezomib at first relapse is superior to high-dose dexamethasone and more effective than when given later in relapsed multiple myeloma. Haematologica 90:146\u2013147","journal-title":"Haematologica"},{"key":"12_CR132_12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","volume":"136","author":"C Stapnes","year":"2007","unstructured":"Stapnes C, Doskeland AP, Hatfield K et al (2007) The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 136:814\u2013828","journal-title":"Br J Haematol"},{"key":"12_CR133_12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Maharaj L, Hoare S et al (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor \u03b1 response with clinical activity. J Clin Oncol 24: 2105\u20132212","journal-title":"J Clin Oncol"},{"key":"12_CR134_12","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1074\/jbc.275.8.5565","volume":"275","author":"E Strickland","year":"2000","unstructured":"Strickland E, Hakala K, Thomas PJ, DeMartino GN (2000) Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome. J Biol Chem 275:5565\u20135572","journal-title":"J Biol Chem"},{"key":"12_CR135_12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3816\/CLM.2006.n.050","volume":"7","author":"A Suvannasankha","year":"2006","unstructured":"Suvannasankha A, Smith GG, Juliar BE et al (2006) Weekly bortezomib\/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma 7: 131\u2013134","journal-title":"Clin Lymphoma Myeloma"},{"key":"12_CR136_12","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1078-0432.CCR-07-2249","volume":"14","author":"BA Teicher","year":"2008","unstructured":"Teicher BA (2008) Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 14: 1650\u20131657","journal-title":"Clin Cancer Res"},{"key":"12_CR137_12","doi-asserted-by":"crossref","first-page":"683s","DOI":"10.1200\/jco.2006.24.18_suppl.17537","volume":"24","author":"G Teoh","year":"2006","unstructured":"Teoh G, Tan D, Hwang W et al (2006) Addition of bortezomib to thalidomide, dexamethasone and zoledronic acid (VTD-Z regimen) significantly improves complete remission rates in patients with relapsed\/refractory multiple myeloma. Updated data presented at the 2006 Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol 24:683s","journal-title":"J Clin Oncol"},{"key":"12_CR138_12","doi-asserted-by":"crossref","first-page":"1010a","DOI":"10.1182\/blood.V108.11.1010.1010","volume":"108","author":"E Terpos","year":"2006","unstructured":"Terpos E, Anagnostopoulos A, Heath D et al (2006) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed\/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1-alpha and angiogenic cytokines. Updated data presented at the 2006 Annual Meeting of the American Society of Hematology. Blood 108:1010a\u20131011a","journal-title":"Blood"},{"key":"12_CR139_12","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","volume":"13","author":"SP Treon","year":"2007","unstructured":"Treon SP, Hunter ZR, Matous J et al (2007) Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom\u2019s macroglobulinemia: results of WMCTG Trial 03\u2013248. Clin Cancer Res 13:3320\u20133325","journal-title":"Clin Cancer Res"},{"key":"12_CR140_12","doi-asserted-by":"publisher","first-page":"9421","DOI":"10.1021\/bi00154a014","volume":"31","author":"A Vinitsky","year":"1992","unstructured":"Vinitsky A, Michaud C, Powers JC, Orlowski M (1992) Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31:9421\u20139428","journal-title":"Biochemistry"},{"key":"12_CR141_12","doi-asserted-by":"crossref","first-page":"29860","DOI":"10.1016\/S0021-9258(18)43960-9","volume":"269","author":"A Vinitsky","year":"1994","unstructured":"Vinitsky A, Cardozo C, Sepp-Lorenzino L, Michaud C, Orlowski M (1994) Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 269: 29860\u201329866","journal-title":"J Biol Chem"},{"key":"12_CR142_12","first-page":"6316","volume":"9","author":"PM Voorhees","year":"2003","unstructured":"Voorhees PM, Dees EC, O\u2019Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316\u20136325","journal-title":"Clin Cancer Res"},{"key":"12_CR143_12","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1158\/1078-0432.CCR-07-1293","volume":"13","author":"PM Voorhees","year":"2007","unstructured":"Voorhees PM, Chen Q, Kuhn DJ et al (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in pre-clinical models of multiple myeloma. Clin Cancer Res 13:6469\u20136478","journal-title":"Clin Cancer Res"},{"key":"12_CR144_12","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1158\/1078-0432.CCR-07-0061","volume":"13","author":"J Voortman","year":"2007","unstructured":"Voortman J, Smit EF, Honeywell R et al (2007) A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 13:3642\u20133651","journal-title":"Clin Cancer Res"},{"key":"12_CR145_12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1126\/science.274.5288.784","volume":"274","author":"CY Wang","year":"1996","unstructured":"Wang CY, Mayo MW, Baldwin AS Jr (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-\u03baB. Science 274: 784\u2013787","journal-title":"Science"},{"key":"12_CR146_12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/10577","volume":"5","author":"CY Wang","year":"1999","unstructured":"Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-\u03baB. Nat Med 5:412\u2013417","journal-title":"Nat Med"},{"key":"12_CR147_12","doi-asserted-by":"publisher","first-page":"d1109","DOI":"10.2741\/1057","volume":"8","author":"T Wang","year":"2003","unstructured":"Wang T (2003) The 26S proteasome system in the signaling pathways of TGF-beta superfamily. Front Biosci 8:d1109\u2013d1127","journal-title":"Front Biosci"},{"key":"12_CR148_12","doi-asserted-by":"crossref","first-page":"42a","DOI":"10.1182\/blood.V108.11.129.129","volume":"108","author":"A Wechalekar","year":"2006","unstructured":"Wechalekar A, Gillmore J, Lachmann H, Offer M, Hawkins P (2006) Efficacy and safety of bortezomib in systemic AL amyloidosis-a preliminary report [abstract 129]. Blood 108:42a","journal-title":"Blood"},{"key":"12_CR149_12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tips.2003.11.008","volume":"25","author":"RJ Wojcikiewicz","year":"2004","unstructured":"Wojcikiewicz RJ (2004) Regulated ubiquitination of proteins in GPCR-initiated signaling pathways. Trends Pharmacol Sci 25:35\u201341","journal-title":"Trends Pharmacol Sci"},{"key":"12_CR150_12","doi-asserted-by":"publisher","first-page":"717a","DOI":"10.1182\/blood-2004-12-4941","volume":"106","author":"M Zangari","year":"2005","unstructured":"Zangari M, Barlogie B, Burns MJ et al (2005) Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001\u201337: superior outcome in patients with normal cytogenetics and no prior T. Updated data presented at the 2005 Annual Meeting of the American Society of Hematology. Blood 106:717a","journal-title":"Blood"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-01222-8_12.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T15:54:33Z","timestamp":1634140473000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-01222-8_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"ISBN":["9783642012211","9783642012228"],"references-count":154,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-01222-8_12","relation":{},"ISSN":["0080-0015"],"issn-type":[{"type":"print","value":"0080-0015"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}